Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation

NCT01817959 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Islet Transplantation in Diabetes Mellitus Type 1

Interventions

DRUG: Reparixin
DRUG: Placebo

Sponsor

Dompé Farmaceutici S.p.A